供应NIBSC21/340可溯源抗SARS-CoV-2免疫球蛋白国际标准物质
产品详情如下，更多产品价格和货期，请咨询客服！
The second WHO International Standard for anti-SARS-CoV-2 immunoglobulin is the freeze-dried equivalent of 0.25 mL of pooled plasma obtained from seven individuals recovered from SARS-CoV2 in the United Kingdom between May-August 2020. The source material for the pooling was selected based on antibody titre to resemble similar levels to that of the 1st WHO International Standard 20/136 and solvent-detergent treated to minimise the risk of the presence of enveloped viruses [1]. The preparation has been evaluated in an International Collaborative study[2]. NIBSC21/340
The intended use of the International Standard is for the calibration and harmonisation of neutralisation assays using SARS-CoV-2 early isolates (2020). For the calibration of secondary reagents used in neutralisation assay against variants of concerns the 1st WHO
International Standard for anti-SARS-CoV-2 variants of concern immunoglobulin, NIBSC code 21/338, should be used.The preparation can also be used as an internal reference reagent for the harmonisation of binding antibody assays.
世界卫生组织第二项抗SARS-CoV-2免疫球蛋白国际标准是冻干当量，即从2020年5月至8月间在英国从SARS-CoV2病毒中回收的七名患者获得的0.25 mL混合血浆。根据抗体滴度选择汇集的源材料，使其与第一个世界卫生组织国际标准20/136的水平相似，并对溶剂洗涤剂进行处理，以最大限度地降低包膜病毒的存在风险[1]。一项国际合作研究[2]对该制剂进行了评估。 可溯源抗SARS-CoV-2免疫球蛋白国际标准物质
该国际标准的预期用途是使用严重急性呼吸系统综合征冠状病毒2型早期分离株校准和协调中和分析（2020）。世界卫生组织第一届会议针对关注的变种校准中和试验中使用的二级试剂
应使用抗SARS-CoV-2相关变异毒株免疫球蛋白国际标准，NIBSC代码21/338。该制剂也可用作协调结合抗体分析的内部参考试剂。
部分相关产品如下，更多相关产品的详细信息，请咨询客服，仅供实验室使用。
Related Product
21/338 1st International Standard 2022 Antibodies to SARS-CoV-2 variants of concern
19/298 First WHO International Standard for anti-human papillomavirus type 6 serum 抗人乳头瘤病毒6型血清国际标准
19/300 First WHO International Standard for anti-human papillomavirus type 58 serum 58型抗人乳头瘤病毒血清国际标准
20/146 First WHO International Standard for SARS-CoV-2 RNA SARS-CoV-2 RNA国际标准
20/152 First WHO International Standard for Mycobacterium tuberculosis (H37Rv) DNA for NAT-based assays 结核分枝杆菌（H37Rv）DNA国际标准，用于基于NAT的检测